ABUS Arbutus Biopharma Corporation
Financings ·
Arbutus filed a Schedule TO on August 24, 2026 to start an issuer tender offer for up to US$230 million of its common shares, paid in cash. The filing points to an Offer to Purchase dated the same day, and it does not state the start or expiry dates in its own text.
Arbutus said on August 21, 2026 that it plans a modified Dutch auction tender offer for up to US$230 million of its common shares at US$5.00 to US$5.75 each, funded from cash on hand. The offer has not started, and the company says it needs exemptive relief in Canada and the United States first.
Arbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026.
Moderna agrees to pay a $950.0 million noncontingent lump sum and may owe a further $1.3 billion depending on a Federal Circuit appeal on 28 U.S.C. §1498. Arbutus is entitled to 20% of proceeds after litigation costs, or, if less, tiered low single-digit royalties.
Arbutus Biopharma and Genevant Sciences sued Moderna, Inc. and a Moderna affiliate, which the filing does not name, over patents tied to the MRNA-1273 COVID-19 vaccine. On March 31, 2025 the court moved the patent trial from September 24 to September 29, 2025.
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease. It is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, for chronic hepatitis B. Arbutus stopped its discovery efforts in 2024 to focus on those two programs. It also protects its patented lipid nanoparticle (LNP) technology. Its lawsuit against Pfizer Inc. and BioNTech SE over LNP use in COVID-19 mRNA vaccines is ongoing, and a claim construction ruling in September 2025 construed disputed terms in a manner the company generally considers favorable. On March 3, 2026, Arbutus and Genevant Sciences GmbH entered a settlement agreement with Moderna, Inc. to resolve LNP patent litigation. Moderna will make an aggregate $950.0 million noncontingent lump sum payment on or before July 8, 2026, and a contingent lump sum payment of $1.3 billion depends on a favorable ruling in a limited appeal. Arbutus receives 20% of the noncontingent payment after litigation costs under its license with Genevant, and owns approximately 16% of Genevant's common equity. The company is evaluating a return of capital to shareholders in the third quarter of calendar year 2026.
| Product or program | What it is | Stage |
|---|---|---|
| Imdusiran (AB-729) | GalNAc-conjugated RNA interference therapeutic for chronic hepatitis B | |
| AB-101 | Oral PD-L1 inhibitor for chronic hepatitis B |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $14.1 million | $6.2 million |
| Research and development | $25.2 million | $54.0 million |
| Net income (loss) | -$33.5 million | -$69.9 million |
| Cash from operations | -$39.6 million | -$64.8 million |
| Cash and equivalents | $18.0 million | $36.3 million |
| Short-term investments | $73.5 million | $86.3 million |
Our latest story on this, dated Aug 24, 2026: "Arbutus Biopharma starts tender offer for up to US$230 million of its shares". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 3, 2026: "Arbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 3, 2026: "Arbutus and Genevant settle Moderna LNP patent litigation, $950.0 million due by July 8, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 16, 2026: "Arbutus expects to return up to approximately $230M to shareholders". The story links the filing or release it is based on. Read the story.
Arbutus Biopharma Corporation trades under the ticker ABUS on NASDAQ.
Arbutus Biopharma Corporation is listed on NASDAQ. Our directory also records these other listings: GETTEX:I9DN; LS:A14XMD; LSX:A14XMD.
The SEC Central Index Key (CIK) for Arbutus Biopharma Corporation is 1447028. Its filings are on SEC EDGAR.
197,847,835 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Arbutus Biopharma Corporation under United States.
Our directory classifies Arbutus Biopharma Corporation as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Arbutus Biopharma Corporation is CA03879J1003.
aibio.space lists Arbutus Biopharma Corporation among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious disease. It is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, for chronic hepatitis B. Arbutus stopped its discovery efforts in 2024 to focus on those two programs.
Imdusiran (AB-729): GalNAc-conjugated RNA interference therapeutic for chronic hepatitis B
Offered to buy back its own securities. SEC Form SC TO-I. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,5.02,8.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio